Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer
Authors Chen W, Li T, Wang J, Liang L, Huang D, Yan G, Tian Y, Zhang X, Zhang W
Received 17 October 2018
Accepted for publication 11 May 2019
Published 3 September 2019 Volume 2019:11 Pages 8157—8165
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr Rituraj Purohit
Wenli Chen1, Tao Li1, Jian Wang1, Long Liang1, Dandan Huang1, Gaoshu Yan1, Ye Tian2, Xiaoli Zhang3, Wei Zhang4
1Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan 610041, People’s Republic of China; 2Department of Thoracic Tumor Surgery, The Fifth People’s Hospital of Chengdu, Chengdu 611130, People’s Republic of China; 3Department of Breast and Thyroid Surgery, The Fifth People’s Hospital of Chengdu, Chengdu 611130, People’s Republic of China; 4Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Chengdu 610041, People’s Republic of China
Correspondence: Wei Zhang
Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, No. 55, Section 4, South People’s Road, Chengdu, Sichuan 610041, People’s Republic of China
Tel +86 288 542 0630
Fax +86 288 542 0630
Purpose: Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) to inhibit tumor growth. Nimotuzumab has demonstrated desirable therapeutic activity in various types of tumors. However, the benefit of nimotuzumab for the treatment of cervical cancer is not entirely clear. The present study aimed to investigate the effects of nimotuzumab in the presence of CCRT in the first-line treatment of locally advanced cervical cancer (LACC).
Methods: The therapeutic efficacy and side effects of nimotuzumab combined with concurrent radiochemotherapy (CCRT) were retrospectively assessed in inoperable patients with LACC (stage IIb-IIIb) who were treated using CCRT with or without nimotuzumab.
Results: The complete response rate of study group was significantly better than control group (78.3% vs 50%, P=0.035). The difference in median progression-free survival (PFS) in the two groups was statistically significan (not reach vs 27 months, P=0.037). Multivariate comparisons of prognostic factors in the two groups indicated that both the Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) stage and combined nimotuzumab treatment affected PFS (P<0.05). Although generally tolerable, grade 3–4 toxicities including leukopenia (P=0.025) and hemoglobin (P=0.026) reduction were more frequent in the control group than those in the study group.
Conclusion: These data suggest that combining nimotuzumab with CCRT for the treatment of LACC resulted in extended PFS and higher complete remission rates, without an increased incidence of adverse events.
Keywords: EGFR monoclonal antibody, Nimotuzumab, cervical cancer, concurrent radiochemotherapy, PFS
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]